Nada M. Gamal
Nada M. Gamal has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Abdelhfeez Moshrif
Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt
3 shared publications - Amany S. El-Bahnasawy
Rheumatology Department, Faculty of Medicine, Mansoura University, Dakahlia, Egypt
3 shared publications - Eman F. Mohamed
Rheumatology Unit, Internal Medicine Department, Faculty of Medicine (Girls), Al-Azhar University, Cairo 11651, Egypt
3 shared publications - Faten Ismail
Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt
3 shared publications - Mervat Ismail Abd Elazeem
Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
3 shared publications - Nouran M. Abaza
Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 80
Clinical utility of serum autotaxin in systemic lupus erythematosus: association with disease activity and renal involvement
Background: Emerging evidence indicates that autotaxin (ATX) produced by plasmacytoid dendritic cells contributes to immune dysregulation and the pathogenesis of systemic lupus erythematosus (SLE). ATX is closely associated with type I interferon signaling, highlighting its potential role as a biomarker and key mediator of SLE. The study aimed to assess serum ATX levels in SLE patients compared with healthy controls and to evaluate their associations with clinical manifestations, laboratory findings, and disease activity, with particular emphasis on renal involvement. Patients and methods: The study included 60 SLE patients and 30 age- and sex-matched controls. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K). Patients were classified into those with active lupus nephritis (ALN; renal SLEDAI-2K ≥ 4) and those with no-renal activity (NRA; renal SLEDAI-2K = 0). Serum ATX levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: The patients were 51 females and 9 males, with a mean age of 33.7 ± 9.3 years. Thirty-one patients had ALN and 29 had NRA. Serum ATX levels were significantly higher in SLE patients than in controls (2023.4 ± 1955.6 vs. 932.5 ± 147.6 pg/ml, p < 0.001). Patients with ALN had significantly higher serum ATX levels than those with NRA (2694.9 ± 2557.6 vs. 1305.5 ± 130.7 pg/ml, p < 0.001) and controls ( p < 0.001 in both), whereas no significant difference was observed between NRA and controls ( p = 0.358). Serum ATX demonstrated excellent diagnostic performance in differentiating SLE patients from controls. At a cut-off value of > 1147 pg/ml, it achieved 96.7% sensitivity, 92.9% specificity, with an area under the curve (AUC) of 0.989 ( p < 0.001). It also accurately discriminated ALN patients from those with NRA, at a cut-off value of > 1571 pg/ml, it yielded 90.3% sensitivity, 100% specificity, with an AUC of 0.992 ( p < 0.001). In multivariate regression analysis, only the renal SLEDAI-2K score remained an independent predictor of elevated serum ATX levels (β = 302.2, p = 0.01). Conclusion: Serum ATX may represent a promising biomarker for assessing disease activity in SLE patients, with particular relevance to renal involvement, warranting further validation in larger prospective studies.
- 5 October 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 80
Open AccessClinical utility of serum autotaxin in systemic lupus erythematosus: association with disease activity and renal involvement
Background: Emerging evidence indicates that autotaxin (ATX) produced by plasmacytoid dendritic cells contributes to immune dysregulation and the pathogenesis of systemic lupus erythematosus (SLE). ATX is closely associated with type I interferon signaling, highlighting its potential role as a biomarker and key mediator of SLE. The study aimed to assess serum ATX levels in SLE patients compared with healthy controls and to evaluate their associations with clinical manifestations, laboratory findings, and disease activity, with particular emphasis on renal involvement. Patients and methods: The study included 60 SLE patients and 30 age- and sex-matched controls. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K). Patients were classified into those with active lupus nephritis (ALN; renal SLEDAI-2K ≥ 4) and those with no-renal activity (NRA; renal SLEDAI-2K = 0). Serum ATX levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: The patients were 51 females and 9 males, with a mean age of 33.7 ± 9.3 years. Thirty-one patients had ALN and 29 had NRA. Serum ATX levels were significantly higher in SLE patients than in controls (2023.4 ± 1955.6 vs. 932.5 ± 147.6 pg/ml, p < 0.001). Patients with ALN had significantly higher serum ATX levels than those with NRA (2694.9 ± 2557.6 vs. 1305.5 ± 130.7 pg/ml, p < 0.001) and controls ( p < 0.001 in both), whereas no significant difference was observed between NRA and controls ( p = 0.358). Serum ATX demonstrated excellent diagnostic performance in differentiating SLE patients from controls. At a cut-off value of > 1147 pg/ml, it achieved 96.7% sensitivity, 92.9% specificity, with an area under the curve (AUC) of 0.989 ( p < 0.001). It also accurately discriminated ALN patients from those with NRA, at a cut-off value of > 1571 pg/ml, it yielded 90.3% sensitivity, 100% specificity, with an AUC of 0.992 ( p < 0.001). In multivariate regression analysis, only the renal SLEDAI-2K score remained an independent predictor of elevated serum ATX levels (β = 302.2, p = 0.01). Conclusion: Serum ATX may represent a promising biomarker for assessing disease activity in SLE patients, with particular relevance to renal involvement, warranting further validation in larger prospective studies.
- 13 January 2026
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 48 (2) , 101-105
Clinical relevance of plasma soluble urokinase plasminogen activator receptor (suPAR) in Behçet’s disease
- 13 January 2026
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 48 (2) , 101-105
Clinical relevance of plasma soluble urokinase plasminogen activator receptor (suPAR) in Behçet’s disease
- Open Access
- 8 January 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 667-676
Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
- 8 January 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 667-676
Open AccessRheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
- 16 April 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
- 16 April 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
- Open Access
- 1 April 2022
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 44 (2) , 151-157
Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
- 1 April 2022
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 44 (2) , 151-157
Open AccessClinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
- Open Access
- 1 June 2021
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 43 (3) , 219-224
Detection of hearing loss in rheumatoid arthritis patients using extended high frequency audiometry: Is it related to disease activity and severity?
- 1 June 2021
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 43 (3) , 219-224
Open AccessDetection of hearing loss in rheumatoid arthritis patients using extended high frequency audiometry: Is it related to disease activity and severity?
- Open Access
- 24 July 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (10) , 1599-1611
Rheumatologists’ practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt
The aim of this work is to trace how rheumatologists all over Egypt are approaching the COVID-19 pandemic and what changes it has brought about in the patients’ care with special attention to its effect on vulnerable rheumatic disease (RD) patients. This survey further aims to help inform the rheumatology community about the changes in practice during the COVID-19 pandemic. The survey included 26 questions distributed to University staff members across Egypt members of the Egyptian College of Rheumatology (ECR). It takes 5–10 min to fill out. The practice setting of participating rheumatologists included University Teaching Hospitals that are the main rheumatology and clinical immunology service providers for adults and children RD patients. There was an overall agreement across the country in the responses to the survey that took a median time of 7 min to fill in. Potential changes in rheumatology outpatient practice by staff members evolved since the COVID-19 pandemic. None of the university rheumatology staff members has prescribed chloroquine or HCQ to prevent or treat COVID-19 in a non-hospitalized patient who was not previously on it. Twenty-three recommended decrease/avoid NSAIDs if the RD patient had confirmed COVID-19 or symptoms. There is an agreement to the key emerging frontline role of rheumatologists in treating COVID-19. During the pandemic, RD cases requiring admission were dealt with by several modified strategies. The overall agreement among the different university rheumatology departments during such critical situation has provoked the ECR to consider providing provisional guidelines for dealing with RD patients during this global catastrophe.
- 24 July 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (10) , 1599-1611
Open AccessRheumatologists’ practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt
The aim of this work is to trace how rheumatologists all over Egypt are approaching the COVID-19 pandemic and what changes it has brought about in the patients’ care with special attention to its effect on vulnerable rheumatic disease (RD) patients. This survey further aims to help inform the rheumatology community about the changes in practice during the COVID-19 pandemic. The survey included 26 questions distributed to University staff members across Egypt members of the Egyptian College of Rheumatology (ECR). It takes 5–10 min to fill out. The practice setting of participating rheumatologists included University Teaching Hospitals that are the main rheumatology and clinical immunology service providers for adults and children RD patients. There was an overall agreement across the country in the responses to the survey that took a median time of 7 min to fill in. Potential changes in rheumatology outpatient practice by staff members evolved since the COVID-19 pandemic. None of the university rheumatology staff members has prescribed chloroquine or HCQ to prevent or treat COVID-19 in a non-hospitalized patient who was not previously on it. Twenty-three recommended decrease/avoid NSAIDs if the RD patient had confirmed COVID-19 or symptoms. There is an agreement to the key emerging frontline role of rheumatologists in treating COVID-19. During the pandemic, RD cases requiring admission were dealt with by several modified strategies. The overall agreement among the different university rheumatology departments during such critical situation has provoked the ECR to consider providing provisional guidelines for dealing with RD patients during this global catastrophe.